Progression of Nephropathy in Spontaneous Diabetic Rats Is Prevented by OPB-9195, a Novel Inhibitor of Advanced Glycation
Open accessThe DOI matches its Crossref record.
Abstract
Levels of tissue advanced glycation end products (AGEs) that result from nonenzymatic reactions of glucose and proteins are high in both diabetic and aging people. Irreversible AGE formation is based on increases in AGE-derived protein-to-protein cross-linking and is considered to be a factor contributing to the complications of diabetes. A novel inhibitor of advanced glycation, OPB-9195, belongs to a group of thiazolidine derivatives, known as hypoglycemic drugs; however, they do not lower blood glucose levels. We did studies to determine if OPB-9195 would prevent the progression of nephropathy in spontaneous diabetic rats. In vitro inhibitory effects of OPB-9195 on AGE formation and AGE-derived cross-linking were examined by enzyme-linked immunosorbent assay (ELISA) and SDS-PAGE, respectively. Otsuka-Long-Evans-Tokushima-Fatty (OLETF) rats, a model of NIDDM, were used to evaluate the therapeutic effect of OPB-9195. Light microscopic findings by periodic acid-Schiff (PAS) staining, the extent of AGE accumulation detected by immunohistochemical staining in the kidneys, the levels of serum AGEs by AGE-specific ELISA, and urinary albumin excretion were examined. OPB-9195 effectively inhibited both AGE-derived cross-linking and the formation of AGEs, in a dose-dependent manner in vitro. In addition, the administration of OPB-9195 prevented the progression of glomerular sclerosis and AGE deposition in glomeruli. Elevation of circulating AGE levels and urinary albumin excretion were dramatically prevented in rats, even at 56 weeks of age and with persistent hyperglycemia. We concluded that a novel thiazolidine derivative, OPB-9195, prevented the progression of diabetic glomerular sclerosis in OLETF rats by lowering serum levels of AGEs and attenuating AGE deposition in the glomeruli.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
“Overall, evidence to suggest a pathological role for advanced glycation in diabetic complications primarily comes from rodent studies, which have clearly shown the efficacy of AGE lowering therapies such as pyridoxamine (72, 86, 127, 142), thiamine (29), alagebrium chloride (75, 184, 186), and OPB-9195 (410) as well a…”
BackgroundDiabetes and mitochondrial function: Role of hyperglycemia and oxidative stress
Rolo, A. P., & Palmeira, C. M. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.01.003 · Cited by 1,007
“…in the pathogenesis of diabetic complications has been shown by the partial prevention of two structurally unrelated AGE inhibitors in various functional and structural manifestations of diabetic disease in animal models (Hammes et al., 1991; Soulis-Liparota et al., 1991; Nakamura et al., 1997).”
BackgroundThe Role of Advanced Glycation End Products in Progression and Complications of Diabetes
Goh, S.-Y., & Cooper, M. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1817 · Cited by 987
“OPB-9195 has been shown to prevent the progression of glomerular sclerosis and reduced urinary albumin excretion (88) in association with decreases in renal TGF- and VEGF expression (89).”
BackgroundRadicals and oxidative stress in diabetes
West, I. C. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00259.x · Cited by 913
Du, X., Matsumura, T., Edelstein, D., Rossetti, L., Zsengellér, Z., Szabó, C., & Brownlee, M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18127 · Cited by 832
Hammes, H.-P., Du, X., Edelstein, D., Taguchi, T., Matsumura, T., Ju, Q., Lin, J., Bierhaus, A., Nawroth, P., Hannak, D., et al. (2003) · Nature Medicine · doi:10.1038/nm834 · Cited by 785
“Similarly, AGE inhibitors prevent various functional and structural manifestations of diabetic vascular disease in retina, kidney, nerve and arter”
BackgroundDiabetes and advanced glycation endproducts
Vlassara, H., & Palace, M. R. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.00932.x · Cited by 697
Mechanisms of maturation and ageing of collagen
Bailey, A. J., Paul, R. G., & Knott, L. (1998) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(98)00119-5 · Cited by 672
Advanced Glycation End Products (AGE) and Diabetes: Cause, Effect, or Both?
Vlassara, H., & Uribarri, J. (2014) · Current Diabetes Reports · doi:10.1007/s11892-013-0453-1 · Cited by 594
Bierhaus, A. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00233-2 · Cited by 555
Miyata, T., van Ypersele de Strihou, C., Kurokawa, K., & Baynes, J. W. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00302.x · Cited by 518
Glycoxidation and lipoxidation in atherogenesis
Baynes, J. W., & Thorpe, S. R. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00228-8 · Cited by 514
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice
Yamamoto, Y., Kato, I., Doi, T., Yonekura, H., Ohashi, S., Takeuchi, M., Watanabe, T., Yamagishi, S.-I., Sakurai, S., Takasawa, S., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11771 · Cited by 475
“Open bars, animals not treated with OPB-9195; filled columns, animals treated with OPB-9195.”
BackgroundMethodInfluentialPyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat
Degenhardt, T. P., Alderson, N. L., Arrington, D. D., Beattie, R. J., Basgen, J. M., Steffes, M. W., Thorpe, S. R., & Baynes, J. W. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00207.x · Cited by 378
Schrijvers, B. F., De Vriese, A. S., & Flyvbjerg, A. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0018 · Cited by 353
Diabetes and Advanced Glycoxidation End Products
Huebschmann, A. G., Regensteiner, J. G., Vlassara, H., & Reusch, J. E. B. (2006) · Diabetes Care · doi:10.2337/dc05-2096 · Cited by 330
Novel inhibitors of advanced glycation endproducts
Rahbar, S., & Figarola, J. L. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.08.009 · Cited by 329
AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions
Sanajou, D., Ghorbani Haghjo, A., Argani, H., & Aslani, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.001 · Cited by 313
Chelating Activity of Advanced Glycation End-product Inhibitors
Price, D. L., Rhett, P. M., Thorpe, S. R., & Baynes, J. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108196200 · Cited by 308
Advanced glycation: an important pathological event in diabetic and age related ocular disease
STITT, A. W. (2001) · British Journal of Ophthalmology · doi:10.1136/bjo.85.6.746 · Cited by 306
Advanced glycation end products: A nephrologist's perspective
Raj, D. S. C., Choudhury, D., Welbourne, T. C., & Levi, M. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70189-2 · Cited by 290
Miyata, T., van Ypersele de Strihou, C., Ueda, Y., Ichimori, K., Inagi, R., Onogi, H., Ishikawa, N., Nangaku, M., & Kurokawa, K. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000032418.67267.f2 · Cited by 290
Intervention strategies to inhibit protein carbonylation by lipoxidation‐derived reactive carbonyls
Aldini, G., Dalle‐Donne, I., Facino, R. M., Milzani, A., & Carini, M. (2007) · Medicinal Research Reviews · doi:10.1002/med.20073 · Cited by 289
SUZUKI, D., MIYATA, T., SAOTOME, N., HORIE, K., INAGI, R., YASUDA, Y., UCHIDA, K., IZUHARA, Y., YAGAME, M., SAKAI, H., et al. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v104822 · Cited by 254
Wendt, T., Tanji, N., Guo, J., Hudson, B. I., Bierhaus, A., Ramasamy, R., Arnold, B., Nawroth, P. P., Yan, S. F., D’Agati, V., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000065100.17349.ca · Cited by 239
Complications of Type 1 Diabetes
Melendez-Ramirez, L. Y., Richards, R. J., & Cefalu, W. T. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.009 · Cited by 213
Intervention against the Maillard reaction in vivo
Monnier, V. M. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.08.014 · Cited by 196
Chen, J., Huang, X., Halicka, D., Brodsky, S., Avram, A., Eskander, J., Bloomgarden, N. A., Darzynkiewicz, Z., & Goligorsky, M. S. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00364.2005 · Cited by 142
TAGE (toxic AGEs) hypothesis in various chronic diseases
Takeuchi, M., & Yamagishi, S. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2004.02.042 · Cited by 116
AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs?
Dukic-Stefanovic, S., Schinzel, R., Riederer, P., & Münch*, G. (2001) · Biogerontology · doi:10.1023/a:1010052800347 · Cited by 113
Kidney, heart and brain: three organs targeted by ageing and glycation
Frimat, M., Daroux, M., Litke, R., Nevière, R., Tessier, F. J., & Boulanger, E. (2017) · Clinical Science · doi:10.1042/cs20160823 · Cited by 88
Revisiting the oral glucose tolerance test criterion for the diagnosis of diabetes
Davidson, M. B., Schriger, D. L., Peters, A. L., & Lorber, B. (2000) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2000.08024.x · Cited by 40
Metadata
- Authors
- Nakamura, S., Makita, Z., Ishikawa, S., Yasumura, K., Fujii, W., Yanagisawa, K., Kawata, T., & Koike, T.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1997-05-01
- Volume
- 46
- Issue
- 5
- Pages
- 895-899
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W1980643281
- Cited by
- 235
- References
- 0
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.